TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36145073

Group type: EXPERIMENTAL
Intervention: FDDB smartphone app and food database
Number of subjects: 10

Group type: COMPARATOR
Intervention: PRODI® dietary assessment method
Number of subjects: 10
Study: 34330770

Group type: EXPERIMENTAL
Intervention: Intermediate-acting insulin isophane for postoperative afternoon glucose ≥140 mg/dl
Number of subjects: 263

Group type: COMPARATOR
Intervention: Short-acting insulin for fasting glucose ≥200 mg/dl (control)
Number of subjects: 263
Study: 32610254

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (vitamin C, E, alpha‐lipoic acid)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 41
Study: 36066688

Group type: EXPERIMENTAL
Intervention: HPV vaccination information from a man physician-avatar
Number of subjects: 236

Group type: COMPARATOR
Intervention: HPV vaccination information from a woman physician-avatar
Number of subjects: 236
Study: 33938905

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 36334688

Group type: EXPERIMENTAL
Intervention: VONA-100QD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: VONA-200QD
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: VONA-100QD and VONA-200QD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Active arms (VONA-100QD, VONA-200QD)
Number of subjects: 120
Study: 33523756

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 110
Study: 32337566

Group type: EXPERIMENTAL
Intervention: Weekly Osteopathic Manipulative Treatment (OMT) for 12 consecutive weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 25
Study: 34338762

Group type: EXPERIMENTAL
Intervention: Alcohol + Red Bull (RB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alcohol + RB
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Red Bull (RB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alcohol + RB placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 16
Study: 34328290

Group type: EXPERIMENTAL
Intervention: 1,565-nm Nonablative Fractional Laser (NAFL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 10,600-nm Ablative Fractional Laser (AFL)
Number of subjects: 19
Study: 32450106

Group type: EXPERIMENTAL
Intervention: Low dose (5 × 10^10 viral particles)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Middle dose (1 × 10^11 viral particles)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High dose (1.5 × 10^11 viral particles)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 108
Study: 35296713

Group type: EXPERIMENTAL
Intervention: Monoscopic 360 video and stereoscopic sound environments (natural)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monoscopic 360 video and stereoscopic sound environments (urban)
Number of subjects: 60
Study: 32090502

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (arm B)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation plus pharmacological pain management (arm C)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control group (arm A)
Number of subjects: 516
Study: 34433773

Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Naproxen treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 94
Study: 34419006

Group type: EXPERIMENTAL
Intervention: Far infrared therapy (FIR) applied to the skin above the AVF three times a week for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (observation without treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Far infrared therapy (FIR)
Number of subjects: 0
Study: 32788865

Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 35270504

Group type: EXPERIMENTAL
Intervention: Integrated nutrition rehabilitation intervention (parenting classes, shredded fish/liver/anchovy, optimized complementary feeding)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group receiving existing health services
Number of subjects: 480
Study: 34499685

Group type: EXPERIMENTAL
Intervention: Statin initiation threshold of ASCVD risk ?7.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin initiation threshold of ASCVD risk ?5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin initiation threshold of ASCVD risk ?10%
Number of subjects: 0
Study: 33188960

Group type: EXPERIMENTAL
Intervention: Smart Sleeve compression system (SSB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coban 2 (C2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Profore Lite (PL)
Number of subjects: 30
Study: 32741946

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone therapy
Number of subjects: 0
Study: 35565780

Group type: EXPERIMENTAL
Intervention: Conventional diet (CD)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: MedDiet-physical activity (MD-PA)
Number of subjects: 155

Group type: COMPARATOR
Intervention: MedDiet-high meal frequency (MD-HMF)
Number of subjects: 155
Study: 34961539

Group type: EXPERIMENTAL
Intervention: gls function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: geese function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lme function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lmer function
Number of subjects: 0

Group type: COMPARATOR
Intervention: All four functions
Number of subjects: 0
Study: 36014810

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic formulation (LabinicTM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35421987

Group type: EXPERIMENTAL
Intervention: Enhanced family planning education using a simplified handout from the WHO FP guidance tool.
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Routine family planning counselling following Uganda Ministry of Health guidelines.
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Enhanced family planning education.
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Routine family planning counselling.
Number of subjects: 1004
Study: 33104835

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 581

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 581
Study: 32168208

Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 245
Study: 34753814

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of salbutamol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (2 mL of nebulized sodium chloride)
Number of subjects: 52
Study: 33645864

Group type: EXPERIMENTAL
Intervention: 50% of sensory threshold
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 80% of sensory threshold
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sensory threshold
Number of subjects: 48
Study: 32147200

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support to reach protein and energy goals (n=1015)
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Standard hospital food (n=1013)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support (full cost analysis)
Number of subjects: 2028
Study: 35943099

Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring (HBPM) combined with pharmacist-led case management
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enhanced usual care with HBPM alone
Number of subjects: 120
Study: 33346926

Group type: EXPERIMENTAL
Intervention: Emergency department care and support services for opioid use disorder (OUD)
Number of subjects: 24
Study: 32125298

Group type: EXPERIMENTAL
Intervention: Toothpaste with plant components and bifidobacteria extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Toothpaste based on HAP
Number of subjects: 40
Study: 35077215

Group type: EXPERIMENTAL
Intervention: Combined ultrasound and electrostimulation (CUSECS) with standard wound care treatment twice a week for 8 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard wound care treatment once a week for 8 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined ultrasound and electrostimulation (CUSECS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard wound care treatment
Number of subjects: 11
Study: 32847664

Group type: EXPERIMENTAL
Intervention: Child life interventions (CLIs) by a certified child life specialist, two 30‐minute sessions
Number of subjects: 30
Study: 36112378

Group type: COMPARATOR
Intervention: Single-dose intravenous antibiotic (cloxacillin 2 g per dose)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous antibiotic (cloxacillin 2 g per dose over 24 hours)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Single-dose intravenous antibiotic
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous antibiotic
Number of subjects: 698
Study: 33274674

Group type: EXPERIMENTAL
Intervention: Direct oral feeding
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (nil-per-mouth for 5 days and subsequent tube feeding)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control
Number of subjects: 132
Study: 35072433

Group type: COMPARATOR
Intervention: Face-to-face preanesthetic interview alone (Group 1)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Videos before the interview (Group 2)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Brochure before the interview (Group 3)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Explanation of different anesthetic techniques by the provider
Number of subjects: 1051
Study: 33845640

Group type: EXPERIMENTAL
Intervention: Three-piece inflatable penile prosthesis (IPP) combined with sildenafil
Number of subjects: 123

Group type: COMPARATOR
Intervention: Three-piece inflatable penile prosthesis (IPP)
Number of subjects: 123
Study: 35259681

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for alcohol harm reduction
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) control
Number of subjects: 180
Study: 32317001

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34854814

Group type: EXPERIMENTAL
Intervention: Playing with a NAO social robot (SR)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Playing with a study nurse
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waiting with parents
Number of subjects: 109
Study: 32654940

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 15558

Group type: COMPARATOR
Intervention: Total hip arthroplasty (THA)
Number of subjects: 15558
Study: 33573765

Group type: EXPERIMENTAL
Intervention: Healthy food density
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Residential location (urban/rural)
Number of subjects: 228
Study: 36127099

Group type: EXPERIMENTAL
Intervention: Gait intervention with minimalist shoes (GIC; n=12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Gait intervention in barefoot condition (GID; n=12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 36
Study: 34963636

Group type: EXPERIMENTAL
Intervention: Early ART (initiation of ART within 2 weeks after randomization)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Deferred ART (initiation of ART 2 weeks after randomization)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 228

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 228
Study: 33577050

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32212888

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 70
Study: 34570315

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence intervention
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence during lockdown
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Perception of pandemic impact on ART adherence
Number of subjects: 280
Study: 33370161

Group type: EXPERIMENTAL
Intervention: SPARK (Sports, Play and Active Recreation for Kids)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinect (exergaming)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 60
Study: 35654318

Group type: EXPERIMENTAL
Intervention: Losartan (AT1R antagonist), single dose
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 33725852

Group type: EXPERIMENTAL
Intervention: Salivary IL-1β levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Salivary MIF levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Bleeding Index
Number of subjects: 111
Study: 33784411

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220µg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 32893024

Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis (DF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham Diacutaneous Fibrolysis (sham-DF)
Number of subjects: 34
Study: 34255874

Group type: EXPERIMENTAL
Intervention: MultiPoint pacing (MPP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: BiV therapy
Number of subjects: 49
Study: 32265363

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low-flow nasal oxygen (LFNO)
Number of subjects: 76
Study: 34491513

Group type: COMPARATOR
Intervention: MD (220 mg/m2)
Number of subjects: 136

Group type: COMPARATOR
Intervention: LD (180 mg/m2)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: SD (260 mg/m2)
Number of subjects: 136
Study: 34798892

Group type: EXPERIMENTAL
Intervention: Cranberry supplementation (144 mg capsule)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 35092535

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel with bevacizumab (CPB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel alone (CP)
Number of subjects: 16
Study: 32979387

Group type: EXPERIMENTAL
Intervention: Prolonged PDA exposure (≥11 days) in infants requiring intubation for ≥10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants requiring <10 days of intubation
Number of subjects: 0
Study: 36071630

Group type: EXPERIMENTAL
Intervention: Breast density notification with health literacy-sensitive information
Number of subjects: 940

Group type: COMPARATOR
Intervention: Breast density notification without health literacy-sensitive information
Number of subjects: 940
Study: 33040600

Group type: EXPERIMENTAL
Intervention: mPCNL
Number of subjects: 60

Group type: COMPARATOR
Intervention: SPCNL
Number of subjects: 60
Study: 32250330

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (T) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 35728921

Group type: EXPERIMENTAL
Intervention: Azithromycin 250-mg tablet manufactured at Pfizer Dalian (China)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin 250-mg tablet manufactured at Pfizer Barceloneta (United States)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasted condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fed condition
Number of subjects: 0
Study: 32903168

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty
Number of subjects: 95

Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 95
Study: 32157686

Group type: EXPERIMENTAL
Intervention: Group education and medical nutrition therapy (MNT) sessions provided within 1-2 weeks of GDM diagnosis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing management through GDM clinic or step-up/step-down approaches.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth services to reduce clinic attendance burden.
Number of subjects: 0
Study: 35260388

Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy withdrawal (based on S100A12 and hsCRP levels)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Continuing therapy due to elevated S100A12/hsCRP levels
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (BiKeR registry, therapy withdrawal without biomarker-based stratification)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy withdrawal
Number of subjects: 119
Study: 35921872

Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg in a 24/4‐day regimen
Number of subjects: 3409
Study: 34893062

Group type: EXPERIMENTAL
Intervention: DA‐3002 (Growtropin®‐II) at 0.14 IU/kg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparator (Genotropin®) at 0.14 IU/kg/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DA‐3002 (Growtropin®‐II)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparator (Genotropin®)
Number of subjects: 58
Study: 32511726

Group type: EXPERIMENTAL
Intervention: Internet-based CBT-I program (SHUTi)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Internet-based patient education (PE)
Number of subjects: 303
Study: 35320161

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus over 10 min, followed by 1.5 mg/kg/h infusion for 24 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (placebo administered at the same rate as lidocaine)
Number of subjects: 90
Study: 33109923

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 32473046

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 133

Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 133
Study: 35787943

Group type: EXPERIMENTAL
Intervention: Tegoprazan (50 mg tablet, once daily) and Naproxen (500 mg tablet, twice daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tegoprazan and Aceclofenac (100 mg tablet, twice daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tegoprazan and Celecoxib (200 mg capsule, twice daily)
Number of subjects: 46
Study: 34187840

Group type: EXPERIMENTAL
Intervention: Fast fluid infusion (0.90% saline)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: 0.90% saline
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: 0.45% saline
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Fast fluid infusion
Number of subjects: 714

Group type: COMPARATOR
Intervention: Slow fluid infusion
Number of subjects: 714
Study: 36012011

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) twice a week at 75% intensity of one‐repetition maximum for 10 weeks during winter
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CT) that did not perform ST
Number of subjects: 18
Study: 35446449

Group type: EXPERIMENTAL
Intervention: 5-session family behavioral intervention (FBI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Crossover group (received FBI in the second 6-months)
Number of subjects: 94
Study: 32026701

Group type: EXPERIMENTAL
Intervention: Integrated transitional care program (ongoing rehabilitation at home through multidisciplinary team)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Secondary stroke prevention (control group)
Number of subjects: 98
Study: 35645037

Group type: EXPERIMENTAL
Intervention: 1500 mg cefuroxime sodium plus 500 mg intravenous azithromycin (experimental group)
Number of subjects: 242

Group type: COMPARATOR
Intervention: 1500 mg cefuroxime sodium plus placebo (placebo group)
Number of subjects: 242
Study: 33853037

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (experimental therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competing risk analyses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kaplan-Meier (KM) methods
Number of subjects: 0
Study: 33259240

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A (BTX‐A) injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cystoscopic hydrodistention
Number of subjects: 36
Study: 35439645

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control (no estrogen therapy)
Number of subjects: 207
Study: 34769896

Group type: EXPERIMENTAL
Intervention: 12-week guided recreational skiing program (average of 28.5 ± 2.6 skiing days)
Number of subjects: 48
Study: 32105387

Group type: EXPERIMENTAL
Intervention: Lumbar intrathecal fentanyl (FENT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 35979703

Group type: EXPERIMENTAL
Intervention: EES + PFMT
Number of subjects: 51

Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 51

Group type: COMPARATOR
Intervention: EES
Number of subjects: 51
Study: 33525419

Group type: EXPERIMENTAL
Intervention: Oral probiotic Weissella cibaria CMU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35964961

Group type: EXPERIMENTAL
Intervention: Smart Optometry application
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional distance VA chart screening
Number of subjects: 100

Group type: COMPARATOR
Intervention: Near vision E chart
Number of subjects: 100
Study: 34684621

Group type: EXPERIMENTAL
Intervention: 3 g MSM daily for 16 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (white rice flour)
Number of subjects: 22
Study: 32697532

Group type: EXPERIMENTAL
Intervention: Breast angiosarcoma patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients who died
Number of subjects: 13
Study: 36321379

Group type: EXPERIMENTAL
Intervention: nCRT (neoadjuvant chemoradiotherapy)
Number of subjects: 327

Group type: COMPARATOR
Intervention: nCT (chemotherapy)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: nCRT
Number of subjects: 327

Group type: COMPARATOR
Intervention: nCT
Number of subjects: 327